Proactiveinvestors recommends

Toro Energy: Environmental approval recommended for Wiluna Uranium Project
Mutiny Gold: Is Deflector one of the best undeveloped orebodies in Australia?
Globe Metals & Mining’s Mark Sumich talks Chinese funding and the upcoming DFS at One2One Forum

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	CIR
Latest Price:	0.43 (-2.27% )
52-week High:	0.65
52-week Low:	0.43
Market Cap:	19.95M

1 year chart

1 day chart

Circadian Technologies

Circadian Technologies (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.

Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply.

Circadian Technologies: Van Leeuwenhoeck places share price target of $1.97

Tuesday, October 11, 2011 by Proactive Investors

Circadian Technologies (ASX: CIR) has received a glowing valuation from Van Leeuwenhoeck Research, which is a firm specialising in bio technology and life science sectors, and based in The Hague and in New York.

The following is an extract from the report.

Executive Summary

Circadian Technologies is an Australia-based listed biotechnology company having a strong product pipeline which includes VGX-100 (a fully human antibody against VEGF-C), VGX-200 (a humanized antibody against VEGF-D) and VGX-300 (a soluble recombinant form of VEGFR-3).

Circadian develops and commercialize therapies primarily for cancer, as well as for other serious diseases.

The Company is engaged in the development of biological drugs, including antibodies, for the treatment of cancer, targeted against Vascular Endothelial Growth Factors (VEGF) C, D and the VEGFR-3 receptor as well as developing a rage of in vitro diagnostics.

During the fiscal year ended June 30, 2010 the Company developed a production manufacturing process for VGX-100 and completed the production of drug compound for use in animal pharmacokinetic and toxicology studies.

Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, brain, ovarian and prostate cancers. Besides, VGX-100 significantly reduces the metastatic spread of prostate cancer in a mouse model. VGX-100 is covered by a variety of US and international patents extending beyond 2022.

End of last month the company announced that it has submitted an IND application to the FDA to initiate clinical studies of VGX-100. The Phase I dose escalation study will involve the treatment of a variety of different cancer types in patients with late stage cancer.

Circadian intends to initiate clinical trials of VGX-100 in Q4 2011.

Earlier last month, the company announced the publication of data, which showed that VGX-100 significantly reduced inflammation and corneal epitheliopathy in Dry Eye Disease (DED).

DED is a complex immune mediated disorder that has multiple cuases and affects about 5 million Americans above the age of 50 years. Currently, topical cyclosporine-A is the only approved treatment for DED.

With more than AUD 22 million in cash, the company continues to have a strong financial position. This should be enough to take its lead drug VGX-100 through Phase I and Phase II trials. With the start of clinical trials, the company expects for 2012FY a cash burn of AUD 10-12.5 million.

Valuation

Based on sum-of-the-parts valuation, we believe Circadian is gravely undervalued at the current share price of AUD 0.47. Using our valuation model, the Company’s total value is AUD 91 million, or A$1.97 per share.

This represents more than 300% upside from the current share price.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.